TICKERNERD
Menu
IRMDIRMDHealthcare · Medical Devices

IRMD Stock Forecast: IRadimed Corp. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$90
+0.20% on the day

The 3 Wall Street analysts covering IRadimed Corp. hold a median 12-month price target of $118 — +31.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.1B
Ticker Nerd rank
92 / 100
Median analyst target
$118
Analysts covering
3
Revenue$20.5M+0.3% y/y
Operating income$6.4M
Net income$5.2M
Free cash flow$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.1%
1M
+8.8%
YTD
−7.1%
1Y
+24.3%
From 52W high
−14.2%
From 52W low
+24.5%
$72
$105
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IRMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IRadimed Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Quality
94
Momentum
81
Revisions
77
Value
76
Issuance
64
Growth
60
Size
42
Accruals
38

Volatility (99): The share price has been relatively steady.

Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IRMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26IRMDHigh $120Median $118Low $116

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $116Median $118High $120

The green dot is the last close — the median target sits +31.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Sept 2026NeedhamInitiatesHold—
2 Apr 2026Freedom BrokerInitiatesBuy$116
2 Apr 2026Freedom BrokerInitiatesBuy—
14 Feb 2025Roth MKMReiteratesBuy—
2 Aug 2024Roth MKMMaintainsBuy—
22 Apr 2024Roth MKMReinstatesBuy$65
2 Aug 2021Roth CapitalMaintainsBuy—
31 July 2017Roth CapitalUpgradeBuy—
5 Oct 2016Roth CapitalDowngradeNeutral—
4 Apr 2016Roth CapitalMaintainsBuy—
16 June 2015Roth CapitalMaintainsBuy—
11 Aug 2014Roth CapitalInitiates——

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IRMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, IRadimed Corp. returned +24.3% against +17.5% for the S&P 500, dividends included.

IRMD vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140150Jan 26Apr 26Jul 26Oct 26IRMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.8%
Analysts raising
2
Analysts cutting
0
Fundamentals

IRadimed Corp. (IRMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
50.2×

Cheaper than 14% of US stocks

Price / sales
13.3×

Cheaper than 11% of US stocks

Price / book
11.3×

Cheaper than 8% of US stocks

EV / EBITDA
37.3×

Cheaper than 6% of US stocks

Growth & margins
Revenue growth (YoY)
0.3%

Higher than 28% of US stocks

Earnings growth (YoY)
−9.6%

Higher than 27% of US stocks

Gross margin
74.1%

Higher than 86% of US stocks

Operating margin
31.2%

Higher than 88% of US stocks

Net margin
26.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
23.5%

Higher than 84% of US stocks

Return on assets
15.6%

Higher than 97% of US stocks

Dividend yield
0.9%

Higher than 69% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IRadimed Corp. (IRMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IRadimed Corp. has a market value of $1.1B and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $86.3M. The latest quarter grew 0.3% year on year.

  • Net income over the same four quarters: $23.1M, a 26.7% net margin.

  • Diluted earnings per share, trailing twelve months: $1.79.

  • Free cash flow in the twelve months to 30 June 2026: $24.5M, after $572K of capital spending.

  • IRadimed Corp. spent $15.8M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 12.8M.

  • Trailing P/E: 50.2×; forward P/E: 36.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.89%, paying out 41% of earnings.

  • IRadimed Corp. employs 166 people — $520K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

IRMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
IRMDIRadimed Corp.$1.1B
92
BVSBioventus, Inc.$1.1B
98
TNDMTandem Diabetes Care, Inc.$1.1B
63
ENOVEnovis Corp.$1.1B
79
AORTArtivion, Inc.$1.0B
40
IARTIntegra LifeSciences Holdings Corp.$1.0B
82
LMRILumexa Imaging Holdings, Inc.$998.6M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IRadimed Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IRMD news & analysis

IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference

GlobeNewsWire · 23 Sept 2026neutral

IRADIMED Corporation announced it will participate in the 5th Annual ROTH Healthcare Opportunities Conference. The company, a provider of MRI-compatible medical devices, made the announcement on September 23, 2026.

Why it matters — The company's participation in a healthcare investor conference provides it with a platform to present its business to the investment community.

iRadimed Q2 Earnings Call Highlights

MarketBeat · 31 July 2026neutral

iRadimed reported second-quarter 2026 revenue of $20.5 million, up 0.5% year-over-year, and began general-release production of its new 3870 MRI IV pump system while managing initial manufacturing ramp costs.

Why it matters — The update signals iRadimed's progress in launching the new 3870 MRI IV pump system, a key product for the company, while navigating the costs tied to ramping up production.

IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

IRADIMED Corporation held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha.

Why it matters — IRMD watchers would care because earnings call transcripts provide direct insight into management's commentary on the company's quarterly performance and outlook.

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 31 July 2026neutral

IRADIMED CORPORATION reported second-quarter 2026 revenue of $20.5 million, a 0.5% increase over the same period in 2025. The company announced a regular quarterly cash dividend of $0.20 per share, reported GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46, and reaffirmed its full-year 2026 revenue and earnings guidance.

Why it matters — IRMD watchers would care because the results show modest revenue growth and an ongoing dividend payout, while the reaffirmed guidance signals that management expects full-year performance to remain on track.

IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026

GlobeNewsWire · 24 July 2026neutral

IRADIMED CORPORATION announced it will release its second quarter 2026 financial results before market open on July 31, 2026, and will host a conference call at 11:00 a.m. Eastern Time that day to discuss the results with investors.

Why it matters — The conference call gives IRMD shareholders and analysts an opportunity to hear management's discussion of the company's quarterly performance and ask questions directly.

FAQ

Frequently asked questions about IRMD stock

What is the IRMD stock price forecast for 2026-2027?

The 3 Wall Street analysts covering IRadimed Corp. have a median 12-month price target of $118, with estimates ranging from $116 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRMD stock a buy right now?

Of the 3 analysts covering IRadimed Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRadimed Corp. 92 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRMD?

As at 14 Oct 2026, IRadimed Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will IRMD stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +31.4% from the last close, and Ticker Nerd's factor model ranks IRadimed Corp. 92 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRMD stock forecast for 2030?

No analyst covering IRadimed Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $116 to $120 over the next 12 months.

How has IRMD stock performed over the past year?

IRadimed Corp. returned +24.3% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IRadimed Corp. do?

iRadimed Corporation is a medical device company that develops, manufactures, markets, and distributes MRI-compatible patient care solutions. Its product portfolio includes MRI-compatible intravenous infusion pump systems, patient vital signs monitoring systems, ferromagnetic detection devices, and related accessories and disposables designed for use in magnetic resonance imaging environments.

What is the latest news on IRMD?

The most recent item we track (GlobeNewsWire, 23 Sept 2026): "IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference". IRADIMED Corporation announced it will participate in the 5th Annual ROTH Healthcare Opportunities Conference. The company, a provider of MRI-compatible medical devices, made the announcement on September 23, 2026.

Company

About IRadimed Corp.

iRadimed Corporation is a medical device company that develops, manufactures, markets, and distributes MRI-compatible patient care solutions. Its product portfolio includes MRI-compatible intravenous infusion pump systems, patient vital signs monitoring systems, ferromagnetic detection devices, and related accessories and disposables designed for use in magnetic resonance imaging environments. The company’s products are used by hospitals, acute care facilities, and outpatient imaging centers to support patient monitoring and medication delivery during MRI procedures. iRadimed Corporation focuses on equipment engineered with non-magnetic components to help maintain clinical workflow and patient safety in high-field imaging settings. Headquartered in Orlando, Florida, iRadimed Corporation serves customers in the United States and internationally through a specialized medical technology platform centered on MRI-compatible care.

CEO Mr. Roger E. Susi · 166 employees · United States · https://www.iradimed.com